Several mechanisms of innate resistance to BRAF inhibitors (BRAFi) in CRC have been identified, including a rapid EGFR feedback activation [7–9] or MAPK-pathway re-activation through multiple mechanisms [10–13]. The gene discussed is EGFR; the disease is colorectal carcinoma.